Compare SANA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANA | VALN |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.5M | 582.2M |
| IPO Year | 2021 | 2021 |
| Metric | SANA | VALN |
|---|---|---|
| Price | $2.36 | $5.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $8.43 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 2.9M | 21.7K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $4.75 |
| 52 Week High | $5.63 | $12.18 |
| Indicator | SANA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 32.63 | 39.94 |
| Support Level | $2.22 | $5.10 |
| Resistance Level | $3.41 | $5.52 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 20.00 | 18.92 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.